Pfizer Inc. $PFE Stock Holdings Trimmed by FARMERS & MERCHANTS TRUST Co OF LONG BEACH

FARMERS & MERCHANTS TRUST Co OF LONG BEACH lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 58.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,462 shares of the biopharmaceutical company’s stock after selling 20,432 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Pfizer were worth $368,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Curio Wealth LLC increased its stake in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer in the 2nd quarter valued at about $30,000. Darwin Wealth Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new stake in Pfizer during the second quarter worth about $33,000. 68.36% of the stock is currently owned by institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: New oncology data showed a Pfizer cancer combination produced stronger tumor shrinkage versus standard treatment in advanced colorectal cancer — supportive for commercial/label expansion prospects in a high‑value oncology indication. Pfizer cancer combo shows strong tumor shrinkage in colorectal cancer trial
• Positive Sentiment: Pfizer advanced a lung‑cancer combo into a global Phase 2/3 program and launched a head‑to‑head colorectal cancer Phase 3 for PF‑08634404 — progress that de‑risks late‑stage oncology pipeline timing and future revenue potential. Pfizer advances new lung cancer combo in global Phase 2/3 trial
• Positive Sentiment: Positive data on Pfizer’s Braftovi regimen were reported, reinforcing the company’s targeted‑therapy franchise and near‑term oncology catalysts. Positive new data on Pfizer’s Braftovi regimen
• Positive Sentiment: CEO Albert Bourla signaled ambition to build an obesity consumer market comparable to Viagra’s consumer expansion; that, plus the $10B Metsera acquisition, positions Pfizer to capture a potentially large, recurring market if regulatory/launch execution succeeds. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: BMO reiterated a Buy and $30 price target, highlighting oncology, obesity pipeline upside and post‑LOE recovery prospects as key upside drivers. Pfizer: Underappreciated Growth Story
• Neutral Sentiment: Zacks’ preview of Q4 suggests oncology revenue will see steady growth from Seagen ADCs and key brands but be partially offset by pricing and competitive pressures — a mixed operational outlook ahead of earnings. Inside Pfizer’s Oncology Performance Ahead of Q4 Results
• Neutral Sentiment: Broker actions are mixed: UBS flagged the Metsera deal favorably but kept a Neutral stance ($25 PT), and the street average rating is around Hold — indicating uncertainty on near‑term revenue trajectory. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE Pfizer Receives Average “Hold” Rating
• Neutral Sentiment: Pfizer’s JPMorgan presentation material was published (slides/transcript) — useful for detail on strategy and pipeline but not an immediate stock mover absent new guidance. Pfizer Presents at J.P. Morgan Healthcare Conference
• Negative Sentiment: Pfizer stopped a mid‑stage lupus skin trial, removing a smaller autoimmune opportunity and signaling a pipeline setback that may reduce near‑term upside from non‑oncology indications. Pfizer Ends Mid-Stage Lupus Skin Trial
• Negative Sentiment: Analysts and commentators continue to flag legacy risks — a looming patent cliff, rising debt and earnings pressure post‑LOE — which cap valuation upside until clearer revenue recovery paths materialize. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Citigroup initiated coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. UBS Group initiated coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target for the company. Finally, Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $27.88.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.12 on Wednesday. The stock has a market cap of $142.83 billion, a P/E ratio of 14.60 and a beta of 0.47. The firm’s 50-day simple moving average is $25.29 and its 200 day simple moving average is $24.97. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.